Cargando…

Myelin oligodendrocyte glycoprotein antibody-associated disease: characterising clinical disease

Detalles Bibliográficos
Autores principales:	Willis, M. D., Robertson, N. P.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer Berlin Heidelberg 2018
Materias:	Journal Club
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6060774/ https://www.ncbi.nlm.nih.gov/pubmed/29992350 http://dx.doi.org/10.1007/s00415-018-8963-z

Ejemplares similares

Correction to: Myelin oligodendrocyte glycoprotein antibody-associated disease: characterising clinical disease
por: Willis, M. D., et al.
Publicado: (2018)

Multiple sclerosis: early indicators of disease and assessing future risk
por: Willis, M. D., et al.
Publicado: (2020)

Neurotoxicity of novel cancer immunotherapies
por: Willis, M. D., et al.
Publicado: (2019)

Chronic traumatic encephalopathy: identifying those at risk and understanding pathogenesis
por: Willis, M. D., et al.
Publicado: (2017)

Multiple sclerosis and the risk of infection: considerations in the threat of the novel coronavirus, COVID-19/SARS-CoV-2
por: Willis, M. D., et al.
Publicado: (2020)

Genetics of disease severity in multiple sclerosis, Alzheimer’s disease, and Huntington’s disease: rejuvenating genome-wide association studies
por: Hrastelj, James, et al.
Publicado: (2017)

Treatments in Alzheimer’s disease
por: Malik, G. A., et al.
Publicado: (2017)

Repurposing drugs to treat neurological diseases
por: Massey, T. H., et al.
Publicado: (2018)

Monoclonal antibodies for migraine: an update
por: Castle, Daniel, et al.
Publicado: (2018)

The economic burden of chronic neurological disease
por: Wynford-Thomas, R., et al.
Publicado: (2017)

Creutzfeldt–Jacob disease: new directions in diagnosis and therapeutics
por: Al-Ansari, Aseel, et al.
Publicado: (2017)

Response to SARS-CoV-2 vaccination in multiple sclerosis patients on disease modifying therapies
por: Allman, M., et al.
Publicado: (2022)

New treatments in Alzheimer’s disease
por: Pickrell, William O., et al.
Publicado: (2018)

Seizures in Alzheimer’s disease: is there more beneath the surface?
por: Edwards, Marc, et al.
Publicado: (2017)

Clinical patterns in CADASIL
por: Gailani, G., et al.
Publicado: (2022)

Stem cells in the treatment of central nervous system disease
por: McLauchlan, Duncan, et al.
Publicado: (2018)

Sleep disorders in Parkinson’s disease
por: Hawken, Jonathan, et al.
Publicado: (2022)

New ways of looking at an old disease: the reimagination of epilepsy
por: Mitchell, Clinton J., et al.
Publicado: (2016)

Technology-assisted recovery of walking after spinal cord injury
por: MD, Willis, et al.
Publicado: (2019)

The gut microbiome: neurological development and disease
por: Miah, Latif, et al.
Publicado: (2022)

Reversing the trend: interventions to treat intracranial haemorrhage associated with anticoagulation
por: McLauchlan, D., et al.
Publicado: (2016)

Clinical trials in myasthenia gravis
por: Mahmood, A., et al.
Publicado: (2023)

Autoimmune encephalitis: clinical presentation, investigation and treatment
por: Al-Ansari, A., et al.
Publicado: (2021)

Cerebral venous thrombosis: clinical predictors and emerging treatments
por: Al-Ansari, A., et al.
Publicado: (2020)

The role of skin biopsy in differentiating idiopathic Parkinson’s disease from other types of parkinsonism
por: Wynford-Thomas, Ray, et al.
Publicado: (2015)

Idiopathic rapid eye movement sleep behaviour disorder: a potential gateway to the development of disease-modifying treatments in neurodegenerative disorders
por: Peall, K. J., et al.
Publicado: (2016)

Pathophysiology of myelin oligodendrocyte glycoprotein antibody disease
por: Corbali, Osman, et al.
Publicado: (2023)

Clinical trials for cerebellar ataxia
por: Schroeder, Benjamin E., et al.
Publicado: (2022)

Amyotrophic lateral sclerosis: an update on treatments from clinical trials
por: Wynford-Thomas, Ray, et al.
Publicado: (2023)

B cell treatments for multiple sclerosis
por: McLauchlan, D., et al.
Publicado: (2017)

Chronic traumatic encephalopathy: quantifying risk and clarifying pathogenesis
por: McLauchlan, D., et al.
Publicado: (2020)

CGRP and migraine
por: Cauchi, M., et al.
Publicado: (2016)

Neurology and vaccinations: considerations in the context of COVID-19/SARS-COV-2
por: Cauchi, M., et al.
Publicado: (2021)

Intravenous immunoglobulin for inflammatory demyelinating polyneuropathy
por: Talaei, M., et al.
Publicado: (2021)

MRI-guided focused ultrasound: new hope for drug-resistant neurological conditions
por: Bari, S., et al.
Publicado: (2023)

Serum biomarkers in myelin oligodendrocyte glycoprotein antibody–associated disease
por: Kim, Hyunjin, et al.
Publicado: (2020)

Myelin Oligodendrocyte Glycoprotein Antibody-associated Disease with Frequent Cerebellitis
por: Ishikura, Teruyuki, et al.
Publicado: (2022)

Transverse myelitis in myelin oligodendrocyte glycoprotein antibody-associated disease
por: Perez-Giraldo, Gina, et al.
Publicado: (2023)

Cerebral amyloid angiopathy: subtypes, treatment and role in cognitive impairment
por: McLauchlan, D., et al.
Publicado: (2017)

Why antisense could make sense for neurodegeneration
por: Massey, T. H., et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_sek7grhvonokfrnpav1hod2qc9